Wednesday 22 July 2015

Teenager controls HIV infection without drugs for more than 12 years

http://edition.cnn.com/2015/07/20/health/teenager-hiv-functional-cure/index.html?sr=cnnifb
Meera Senthilingam, for CNN

(CNN)A French teenager infected at birth with HIV has shown the ability to control levels of the infection in her body -- without being on antiretroviral treatment.
The finding provides new hope that a "functional" cure for HIV -- where the virus is brought down to low levels but not eradicated in the body -- may one day be possible.
The 18-year-old female, whose mother was HIV positive, was given antiretroviral treatment soon after birth but stopped at age six and has since maintained undetectable levels of the virus in her blood -- known as remission -- for 12 years.
"This is the first [time] long-term remission has been shown in children, or adolescents," said Asier Saez Cirion from the Institut Pasteur in France, who presented the findings at the 8th IAS conference on HIV pathogenesis, treatment and prevention, in Vancouver this week.

World AIDS day 2
World AIDS day 3
New HIV infections globally in 2013-- sub-Saharan Africa continues to have the greatest numbers of new infections.
Vaccines developed over time.

A Pakistani technician takes samples in a laboratory alongside a ribbon promoting World Aids Day in Islamabad on November 30, 2013. Researchers in the United States believe there may finally be an HIV vaccine within 10 years.

Treatment at birth

The researchers believe there may be something unique in her biology that, combined with early treatment, enabled her to control the infection. But for now, the reason remains a mystery.
    She was initially treated with antiretroviral drugs as a prophylactic to prevent infection, and then given a combination of four antiretroviral drugs when the virus was found to persist. She was monitored as part of a group of child HIV patients, but failed to go in for observations between the age of five and six, during which time her family chose to stop her treatment.
    On returning for check-ups one year later, medical teams found undetectable levels of HIV in her blood despite her break from treatment.
    More than 12 years later, the virus remains undetectable.

    Learning from adults

    "We have already found it was possible in adults," said Saez-Ciron. This work follows on from his previous research, in which 14 adults with HIV in France -- known as the "Visconti patients" -- were treated for HIV soon after infection but stopped taking their drugs three years later and showed no resurgence in the amount of virus found in their blood. The group are considered to be post-treatment controllers of the virus.
    Today, 12 remain in control of their infection and without drugs, and they have an average of 10 years in remission.
    What these adults have in common with the French teenager is the early initiation of antiretroviral treatment, thought to aid remission by preventing the formation of HIV reservoirs inside the body.
    "Again, treatment was initiated very close to the period of infection," said Saez-Ciron.
    However, in practice, most adults infected with HIV aren't diagnosed until the virus has taken hold -- making early treatment a challenge. But children at risk of infection from their mothers can be identified -- and treated — during pregnancy, or at birth.
    But pediatric experts warn this kind of remission is not common.

    A rare exception?

    "This case is very rare," said Deborah Persaud, a virologist at Johns Hopkins Children's Centerin Baltimore, who worked on the case of the "Mississippi baby," an infant once believed to have been functionally cured of HIV as a result of immediate treatment with antiretrovirals. No virus was detected for more than two years, before it again showed up in tests.
    Persaud is excited that remission has been achieved for this length of time in the teenager, but warns it is unlikely to be replicated easily. "Many kids have gone off treatment -- and treated that early -- and we haven't seen this outcome," she said. "Parents should not take their child of their antiretroviral regimen to see if they're like this child."
    The team at the Pasteur Institute agrees.
    "The fact that you initiate treatment very early doesn't imply you will achieve remission of infection," said Saez-Ciron.

    The search for a reason

    The team are now exploring the biology behind this ability to control infection in hope of identifying key factors -- or markers -- in the body that could predict the possibility of remission, and ideally a functional cure, in others. It's hoped this form of "cure" would result in virus levels being so low, they no longer do enough damage to the immune system to cause adverse health consequences.
    "Most people are not going to be able to control after treatment interruption, but some can," said Saez-Ciron. "What we are trying to do now is understand why some can and most do not." That could help develop strategies to aid this type of remission in others.
    Nobel laureate Francoise Barre-Sinoussi, who co-discovered HIV in 1983, and works at the Institut Pasteur, said: "We are learning from this patient, that's why it's so exciting.
    "We are learning clearly which kind of response the strategy for the future should use. This is critical if we want to make progress in the field of remission in the future."
    Saez-Ciron also presented the results at the 2015 Towards an HIV Cure symposium, held at the beginning of the conference, in which HIV cure researchers gathered from around the world to hear the latest news in the field.
    The announcement of the case of the French teenager was met with restrained excitement, but also a desire for more examples of this kind of functional cure.
    "Being free of viral rebound is impressive," said Anthony Fauci, head of the U.S. National Institute of Allergy and Infectious Diseases (NIAID), who spoke at the conference."But it's only one case ... as time goes by you [need to] accumulate more evidence."

    Monday 20 July 2015

    Breakthrough global agreement sharply lowers price of early infant diagnosis of HIV

    Home
    http://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2015/july/20150719_EID_pressrelease

    New price could help close children’s HIV treatment access gap
    VANCOUVER/GENEVA, 19 July 2015—Global partners in the Diagnostics Access Initiative have joined with Roche Diagnostics to announce a 35% reduction in the price for HIV early infant diagnostic technologies. The new access price is US$ 9.40 per test, including proprietary reagents and consumables associated with diagnosing HIV in very young children. Partners involved in the negotiation of this reduced access price include UNAIDS, the Clinton Health Access Initiative Inc., the United States President’s Emergency Plan for AIDS Relief (PEPFAR), the Global Fund to Fight AIDS, Tuberculosis and Malaria and UNITAID.
    With peak mortality among children living with HIV occurring at 6-8 weeks, the World Health Organization recommends that all children exposed to HIV receive early infant diagnostic screening within the first two months of life.  However, only around half of children exposed to HIV receive early infant diagnostic screening, in part because costs have limited the number of testing platforms currently used in low- and middle-income countries. This has contributed to a major gap in HIV treatment access, as in 2014 only 32% of children living with HIV received antiretroviral therapy compared with 41% of adults living with HIV. Without knowing the HIV status of a child it is impossible to access life-saving treatment. Without treatment, half of all children born with HIV will die by the age of two and the majority will die by the age of five.
    “This agreement with Roche Diagnostics is a powerful step towards ending the unconscionable failure of the world to meet the treatment needs of children living with HIV,” said UNAIDS Executive Director Michel SidibĂ©. “We now need to use this agreement to rapidly scale up diagnostic and treatment services for all children living with HIV, in line with the 90-90-90 target.”
    The 90-90-90 target provides that by 2020, 90% of all people living with HIV will know their HIV status; 90% of all people with an HIV diagnosis will receive sustained antiretroviral therapy; and 90% of all people receiving antiretroviral therapy will achieve viral suppression.
    “As the leader in HIV diagnostics, Roche is proud to support the UNAIDS 90-90-90 goal by expanding access to quality HIV testing for early infant diagnosis in resource limited settings,” stated Roland Diggelmann, Chief Operating Officer of Roche Diagnostics. “Increased access to early infant diagnosis can provide an impactful contribution for mother and child and contribute to achieving UNAIDS’ goals for controlling and eradicating the HIV/AIDS epidemic.”
    This is the second major pricing agreement that partners in the Diagnostics Access Initiative have forged with Roche Diagnostics. In 2014, these partners, joined by the Government of South Africa, announced a 40% reduction in the global price of the leading platform for HIV viral load testing. The new cost for early infant diagnosis is the same as the one negotiated for viral load testing for adults.
    The UNAIDS-sponsored Diagnostics Access Initiative, launched at the International AIDS Conference in Australia in July 2014, issued a call to the global community to achieve more affordable pricing for viral load testing. Through the leadership of South Africa and in partnership with CHAI, UNAIDS, UNITAID, The Global Fund and the US President’s Emergency Plan for AIDS Relief (PEPFAR), suppliers were challenged to lower viral load prices, and Roche is the first company to step forward and offer the HIV community an access policy that will accomplish these goals. Other partners in the DAI include the World Health Organization, US Centers for Disease Control and Prevention, African Society for Laboratory Medicine and UNICEF.
    “This new agreement reduces prices by 35% for HIV tests for infants," said CHAI Chief Executive Officer Ira C. Magaziner. "This will allow more infants to be tested which will in turn save the lives of many children who will now be able to enter treatment sooner. I congratulate Roche. This represents the latest in a series of agreements where Roche has been a pioneer in bringing state of the art testing to resource poor settings at affordable prices.”
    Leading AIDS financing organizations also welcomed the new agreement.
    “No child should die because early infant diagnostic screening isn’t available.  This price reduction will be a positive step forward to make diagnosis of HIV more widely available and to ensure children exposed to HIV are diagnosed early and receive the life-saving treatment they need," said Ambassador Deborah L. Birx, M.D., U.S. Global AIDS Coordinator and  U.S. Representative for Global Health Diplomacy.
    “This agreement builds on and supports other efforts of a strong partnership to make the market for viral load testing more competitive and transparent, and that better serves children affected by HIV,” said Mark Dybul, Executive Director of the Global Fund.
    UNAIDS
    The Joint United Nations Programme on HIV/AIDS (UNAIDS) leads and inspires the world to achieve its shared vision of zero new HIV infections, zero discrimination and zero AIDS-related deaths. UNAIDS unites the efforts of 11 UN organizations—UNHCR, UNICEF, WFP, UNDP, UNFPA, UNODC, UN Women, ILO, UNESCO, WHO and the World Bank—and works closely with global and national partners towards ending the AIDS epidemic by 2030. Learn more at unaids.org and connect with us on Facebook and Twitter.